within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B05B_IVSolutions.B05BB04_ElectrolytesInCombinationWithOtherDrugs;
model ElectrolytesInCombinationWithOtherDrugs 
   extends Pharmacolibrary.Drugs.ATC.B.B05BB04;

  annotation(Documentation(
    info ="<html><body><p>Electrolytes in combination with other drugs (ATC code B05BB04) are formulations used primarily for parenteral rehydration, correction of electrolyte imbalances, and support of homeostasis in various clinical settings, such as perioperative care, intensive care, or treatment of dehydration and shock. These combinations frequently contain ions such as sodium, potassium, chloride, calcium, magnesium, and may include glucose or other adjuvants. These are widely approved and commonly used in hospital and emergency medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are generally not well characterized or specified for these mixtures, because the pharmacokinetics of electrolytes depend on the individual ions and clinical status of a patient. No published studies directly reporting compartmental pharmacokinetic models or parameters for this ATC code combination have been identified in the literature.</p><h4>References</h4><ol><li><p>Maguire, WF, et al., &amp; Appleman, LJ (2021). Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 88(4) 643–654. DOI:<a href=&quot;https://doi.org/10.1007/s00280-021-04317-y&quot;>10.1007/s00280-021-04317-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34164713/&quot;>https://pubmed.ncbi.nlm.nih.gov/34164713</a></p></li><li><p>Ward, A, &amp; Heel, RC (1984). Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. <i>Drugs</i> 28(5) 426–464. DOI:<a href=&quot;https://doi.org/10.2165/00003495-198428050-00003&quot;>10.2165/00003495-198428050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6391889/&quot;>https://pubmed.ncbi.nlm.nih.gov/6391889</a></p></li><li><p>Torka, P, et al., &amp; Griffiths, EA (2016). Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. <i>Blood reviews</i> 30(3) 201–211. DOI:<a href=&quot;https://doi.org/10.1016/j.blre.2015.11.004&quot;>10.1016/j.blre.2015.11.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26709030/&quot;>https://pubmed.ncbi.nlm.nih.gov/26709030</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end ElectrolytesInCombinationWithOtherDrugs;
